Marietta Wu, a managing director with Quan Capital, sees promise in an ophthalmic biotech company. Quan co-led Eluminex Biosciences, Ltd.’s $50 million Series A round with Lilly Asia Ventures and GL Ventures.
Based in Shanghai, Eluminex was founded earlier this year and is focused on developing novel therapeutics for the benefit of patients with vision-threatening eye diseases. In a statement, Marietta said Quan sees Eluminex’s management team as having the ability to “build a leader in ophthalmology with accelerated development of novel therapeutics.”
In conjunction with the financing, Marietta joined Eluminex’s board. She is also on the boards of Citrine, Crescendo Biologics, Innoforce, Kira Pharmaceutical, MEDx Translational Medicine and Zidan Medical.
Marietta formed Quan with Samantha Du and Stella Xu.